This stock is a great choice for cautious and aggressive investors.

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

Alphabet is the most complete end-to-end AI company on the planet, and the advantages of its vertical integration and its ...

Palo Alto Networks will significantly expand the scope of the cybersecurity offerings it makes available on Google Cloud in the New Year while at the same ...

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...

A Liverpool ECHO investigation examines the current situation at The Triad building in Bootle town centre, as plans are ...

While the funding winter persists, the region’s fundamentals and strategic advantages have never been more compelling Read ...

I have two cats, and there’s nowhere in my home that doesn’t end up riddled with pet hair. An effective vacuum isn’t just a nice-to-have—it’s a necessity to clear the house of allergy-causing dander.

AI is enabling organisations to build bigger and faster than ever before. But amidst the excitement of these new possibilities, new pitfalls are emerging ...

Microsoft in November launched a managed memory feature for its Foundry Agent Service, enabling enterprise AI agents to ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...